Nivolumab companion diagnostic - Dako/ONO Pharmaceutical

Drug Profile

Nivolumab companion diagnostic - Dako/ONO Pharmaceutical

Alternative Names: PD-L1 IHC 28-8 pharmDx

Latest Information Update: 29 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dako A/S; Ono Pharmaceutical
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Head and neck cancer; Non-small cell lung cancer
  • Registered Malignant melanoma

Most Recent Events

  • 15 May 2017 Launched for Head and neck cancer (Diagnosis) in European Union, Norway, Norway, Liechtenstein and Iceland (unspecified route)
  • 15 May 2017 Registered for Head and neck cancer (Diagnosis) in European Union, Liechtenstein, Norway and Iceland (unspecified route)
  • 11 May 2016 Registered for Malignant melanoma (Diagnosis) in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top